Clinical Trials Browser

Phase 2 × Waldenstrom Macroglobulinemia × Pharmacogenomic Variants × Clear all

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia